David against Goliath: may we target and defeat interstitial lung disease in systemic sclerosis

David against Goliath: may we target and defeat interstitial lung disease in systemic sclerosis?

I. Miniati, M.L. Conforti, S. Guiducci, M. Matucci Cerinic

Dept of Medicine, Division of Rheumatology, DenoThe center, University of Florence, Italy.

Key words

Cyclophosphamide, mycophenolate mofetil, interstitial lung disease, systemic sclerosis, scleroderma.

Please address correspondence to: Irene Miniati, Div. Rheumatology, Villa Monna Tessa, Viale Pieraccini 18 50139 Firenze, Italy.

Clin Exp Rheumatol 2007; 25: 169-171